Reviewing Perspective Therapeutics (CATX) & Its Rivals

Perspective Therapeutics (NASDAQ:CATX) is one of 29 publicly-traded companies in the “Surgical, Medical, And Dental Instruments And Supplies” industry, but how does it compare to its rivals? We will compare Perspective Therapeutics to related companies based on the strength of its dividends, analyst recommendations, institutional ownership, profitability, earnings, valuation and risk.

Risk and Volatility

Perspective Therapeutics has a beta of 1.75, indicating that its stock price is 75% more volatile than the S&P 500. Comparatively, Perspective Therapeutics’ rivals have a beta of 1.76, indicating that their average stock price is 76% more volatile than the S&P 500.

Profitability

This table compares Perspective Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Perspective Therapeutics	N/A	N/A	N/A
Perspective Therapeutics Competitors	-672.41%	-133.75%	-59.01%

Insider and Institutional Ownership

54.7% of Perspective Therapeutics shares are owned by institutional investors. Comparatively, 22.5% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are owned by institutional investors. 3.7% of Perspective Therapeutics shares are owned by insiders. Comparatively, 18.1% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Perspective Therapeutics and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perspective Therapeutics	0	0	6	0	3.00
Perspective Therapeutics Competitors	77	77	156	6	2.29

Perspective Therapeutics currently has a consensus price target of $11.17, indicating a potential upside of 122.00%. As a group, “Surgical, Medical, And Dental Instruments And Supplies” companies have a potential upside of 38.28%. Given Perspective Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Perspective Therapeutics is more favorable than its rivals.

Earnings & Valuation

This table compares Perspective Therapeutics and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Perspective Therapeutics	N/A	N/A	-5.59
Perspective Therapeutics Competitors	$59.55 million	-$32.15 million	4.35

Perspective Therapeutics’ rivals have higher revenue, but lower earnings than Perspective Therapeutics. Perspective Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

Perspective Therapeutics beats its rivals on 7 of the 12 factors compared.

About Perspective Therapeutics

Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. Isoray, Inc. was founded in 1998 and is based in Richland, Washington.